New insulin boosts artificial pancreas performance in type 1 diabetes trial
NCT ID NCT05508061
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a faster-acting insulin (Lyumjev) works better than standard insulin (Humalog) in a dual-hormone artificial pancreas for people with type 1 diabetes. Twelve adults who already used the artificial pancreas took part. Each person used both insulins for 30 days to compare glucose control and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Insulin Lispro (Lyumjev and Humalog)
What this could lead to
If Lyumjev works better, it could improve blood sugar control and reduce high glucose episodes for people using an artificial pancreas.
What could go wrong
This is a small, early-stage trial with only 12 people. Results may not apply to everyone, and faster insulin could increase hypoglycemia risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Gelderse Vallei
Ede, Gelderland, 6716 RP, Netherlands
-
Rijnstate Hospital
Arnhem, Gelderland, 6815 AD, Netherlands
-
Slingeland Hospital
Doetinchem, Gelderland, 7009 BL, Netherlands